Feasibility and accuracy of continuous glucose monitoring in surgical intensive care unit patients: a single-center pilot study in South Korea
Acute and Critical Care · 31.05.2026 · 41 (2) · 378-386
DOI: 10.4266/acc.004975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acute and Critical Care, erschienen am 31.05.2026. Verfasst von Hyojun Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Intensivpflege
Abstract (Originalsprache)
Background
Continuous glucose monitoring (CGM) technology offers potential advantages over intermittent point-of-care testing in critically ill patients by providing real-time glucose trends and automated alerts. However, its accuracy and feasibility in intensive care settings require validation before widespread implementation.
Methods
We conducted a single-center observational pilot study, evaluating CGM feasibility in 11 surgical intensive care unit (ICU) patients, including nine post–liver transplant recipients. The G6 CGM system was applied for continuous monitoring. CGM readings were paired with point-of-care glucose measurements for accuracy assessment. Performance metrics included the mean absolute relative difference (MARD), bias, standard deviation of relative differences (SDRD), Surveillance Error Grid (SEG) analysis, and International Organization for Standardization (ISO) 15197:2013 criteria compliance.
Results
During a median monitoring period of 5 days (interquartile range [IQR], 3–9), we analyzed 326 paired glucose measurements. CGM demonstrated acceptable accuracy, with a MARD of 13.5% (95% CI, 11.43%–15.76%), bias of 2.79% (95% CI, –2.48 to 7.27%), and SDRD of 18.69% (95% CI, 13.75%–23.65%). SEG analysis confirmed 99.1% of readings were in clinically acceptable zones A and B. ISO 15197:2013 criteria showed 62.9% of measurements were within ±15 mg/dl or ±15%. The median patient-level mean glucose was 199.0 mg/dl (IQR, 162.0–248.0), reflecting substantial hyperglycemic exposure in patients receiving high-dose methylprednisolone despite protocolized insulin therapy targeting a range of 140–180 mg/dl.
Conclusions
CGM was feasible and acceptably accurate in ICU patients. Persistent hyperglycemia despite protocolized care indicates that CGM-derived data may help to identify opportunities for future protocol improvement. Its potential impact on the time-in-target range, hypoglycemia, and clinical outcomes should be evaluated in future multicenter studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University College of Medicine, Seoul, Korea.
Zitieren
APA
Park, H., Gil, E., Lee, J. H., & Park, C. M. (2026). Feasibility and accuracy of continuous glucose monitoring in surgical intensive care unit patients: a single-center pilot study in South Korea. Acute and Critical Care, 41(2), 378-386. https://doi.org/10.4266/acc.004975
Vancouver
Park H, Gil E, Lee JH, Park CM. Feasibility and accuracy of continuous glucose monitoring in surgical intensive care unit patients: a single-center pilot study in South Korea. Acute and Critical Care. 2026;41(2):378-386. doi:10.4266/acc.004975
BibTeX
@article{Park2026,
author = {Park, Hyojun and Gil, Eunmi and Lee, Joon Ho and Park, Chi-Min},
title = {Feasibility and accuracy of continuous glucose monitoring in surgical intensive care unit patients: a single-center pilot study in South Korea},
journal = {Acute and Critical Care},
year = {2026},
volume = {41},
number = {2},
pages = {378--386},
doi = {10.4266/acc.004975}
}
EUVIMED